Status: Recruiting
Efficacy and Safety of Peginterferon in ET and PV.
This is a single-arm, single-center study aims to recruit 40 participants with Essential Thrombocythemia (ET) and Polycythemia Vera (PV). Eligible participants will receive a subcutaneous injection of Peginterferon α-2b 180 mcg once a week and follow-up,and efficacy and safety will be evaluated.
Participants needed: 40
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Zhenya HongUpdated: Dec 16, 2024Locations: 1
Eligibility criteria
Meet the 2016 WHO diagnostic criteria for ET (Essential Thrombocythemia) and PV... [+2]
Previous treatment with Peginterferon α-2b. [+8]